Cargando…
Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
Objectives: We compared outcomes in post-menopausal estrogen receptor-positive (ER+) breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) or neoadjuvant chemotherapy (NACT). Methods: We retrospectively identified post-menopausal women who received either NAHT or NACT for non-metas...
Autores principales: | Marcus, David M., Switchenko, Jeffrey M., Prabhu, Roshan, O’Regan, Ruth, Zelnak, Amelia, Fasola, Carolina, Mister, Donna, Torres, Mylin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873517/ https://www.ncbi.nlm.nih.gov/pubmed/24409418 http://dx.doi.org/10.3389/fonc.2013.00317 |
Ejemplares similares
-
Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy
por: Kandula, Shravan, et al.
Publicado: (2015) -
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy
por: Schlafstein, Ashley J., et al.
Publicado: (2018) -
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023) -
Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer
por: Rudra, Soumon, et al.
Publicado: (2015) -
Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
por: Joshi, Shriya, et al.
Publicado: (2022)